Skip to main content

Table 3 Propensity score analysis results 1: Survival impact across quintiles based on the propensity to receive chemotherapy among patients with metastatic non-small cell lung cancer, who survived at least 3 months after their cancer diagnosis (n = 7,879)

From: The effect on survival of continuing chemotherapy to near death

Analysis

Variables

HR

(95%CI)

P-value

Stratified analysis

    

Lowest quintile of PS*

No chemotherapy

1.00

-

-

 

Chemotherapy

0.82

(0.73, 0.93)

< 0.01

Second quintile of PS

No chemotherapy

1.00

-

-

 

Chemotherapy

0.77

(0.69, 0.85)

< 0.001

Third quintile of PS

No chemotherapy

1.00

-

-

 

Chemotherapy

0.81

(0.74, 0.90)

< 0.001

Fourth quintile of PS

No chemotherapy

1.00

-

-

 

Chemotherapy

0.85

(0.77, 0.93)

< 0.01

Highest quintile of PS

No chemotherapy

1.00

-

-

 

Chemotherapy

0.73

(0.66, 0.81)

< 0.001

Multiple Cox regression adjustment using the PS

No chemotherapy

1.00

-

-

 

Chemotherapy

0.76

(0.71, 0.82)

< 0.001

  1. Abbreviation: HR, hazard ratio; CI, confidence interval; PS, propensity score.
  2. * Patients are least likely to receive "chemotherapy."
  3. † Patients are most likely to receive "chemotherapy."